Analysts Estimates And Ratings CytRx Corporation (CYTR)
The share price of the company (CYTR) was down -0.10%, with a high of 0.71 during the day and the volume of CytRx Corporation shares traded was 4357513.
During the trading day, the stock price fluctuated between $0.67 and $0.76. The stock had a trading volume of 19,565,088 shares.
Insider Trading is buying and selling of a security by a person who has access to material information related to a security that is not available to general public. For instance, insider trading is illicit when the trader has special information, which is not available to other shareholders. They now have a United States dollars 10 price target on the stock. EPS breaks down the profitability of the company on a single share basis. It is used to find out how fast a business is expanding. Subsequently, the points are added up to determine the best value stocks. The company’s average Piotroski F-Score: 4 during the last 7 years.
FCF is an indicator of a firm’s financial performance, measured as operating cash flow minus capital expenditures.
Management effectiveness shows return on equity and return on assets for the trailing twelve months at -203.86% and -48.64% respectively.
Cytrx Cp (NASDAQ:CYTR) as of recent trade, has shown weekly upbeat performance of 16.99% which was maintained at 33.39% in 1-month period.
It is the net asset value of a company, calculated as total assets minus intangible assets and liabilities. The company has an Average True Range (ATR) value of 0.08, while a Beta Value of 2.27.
CytRx Corporation’s average Book Value per Share Growth Rate was -75.4 percent during the past 12 months.
CytRx Corporation (CYTR) has a market capitalization of 102.29 Million which suggests the company is a huge company further suggesting that the shares of CytRx Corporation (CYTR) are stable and safe compared to the lower market capitalization companies.
The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. On average, equities analysts expect that CytRx Corporation will post ($0.50) earnings per share for the current year. For the quarter, shares have been noted at 66.02%. Accern also gave news headlines about the biotechnology company an impact score of 46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Average Revenue Estimate for the current quarter is $11.42 Million, according to consensus forecast of 1 analysts. The high and low revenue estimates for the current quarter are $11.42 Million and $11.42 Million, respectively. The company had Year Ago Sales of $132.55 Million.